Table 1 Characteristics of 2514 women with incident stage I-III breast cancer included in the final cohort
From: HbA1c levels and breast cancer prognosis in women without diabetes
Characteristics | Total N = 2,514 | HbA1c-Q1 21–33 mmol/mol N = 649 | HbA1c-Q2 34-36 mmol/mol N = 794 | HbA1c-Q3 37-38 mmol/mol N = 485 | HbA1c-Q4 \(\:\ge\:\)39 mmol/ N = 586 |
|---|---|---|---|---|---|
Age, median (IQR) | 62 (52–69) | 52 (47–64) | 61 (52–68) | 64 (58–71) | 67 (59–73) |
Age (years), categories | |||||
< 50 | 441 (17.5%) | 229 (35.3%) | 137 (17.3%) | 42 (8.7%) | 33 (5.6%) |
50–59 | 639 (25.4%) | 181 (27.9%) | 228 (28.7%) | 112 (23.1%) | 118 (20.1%) |
60–69 | 852 (33.9%) | 156 (24.0%) | 274 (34.5%) | 198 (40.8%) | 224 (38.2%) |
\(\:\ge\:\) 70 | 582 (23.2%) | 83 (12.8%) | 155 (19.5%) | 133 (27.4%) | 211 (36.0%) |
Missing | 0 | 0 | 0 | 0 | 0 |
Body Mass Index (kg/m2), median (IQR) | 24.74 (22.20-28.09) | 23.51 (21.56–25.94) | 24.34 (22.04–27.48) | 25.06 (22.15–28.24) | 27.10 (24.11–31.23) |
Body Mass Index, categories (kg/m2) | |||||
Underweight < 18.5 | 62 (2.5%) | 16 (2.5%) | 22 (2.8%) | 15 (3.1%) | 9 (1.6%) |
Normal weight 18.5 \(\:\le\:\) to < 25 | 1,229 (49.6%) | 406 (63.6%) | 418 (53.4%) | 219 (45.6%) | 186 (32.3%) |
Overweight 25 ≤ to < 30 | 769 (31.1%) | 163 (25.5%) | 231 (29.5%) | 171 (35.6%) | 204 (35.5%) |
Obesity ≥ 30 | 416 (16.8%) | 53 (8.3%) | 112 (14.3%) | 75 (15.6%) | 176 (30.6%) |
Missing | 38 | 11 | 11 | 5 | 11 |
Menopausal status | |||||
Premenopausal | 584 (23.5%) | 276 (43.0%) | 195 (25.0%) | 64 (13.2%) | 49 (8.5%) |
Postmenopausal | 1902 (76.5%) | 366 (57.0%) | 586 (75.0%) | 420 (86.8%) | 530 (91.5%) |
Missing | 28 | 7 | 13 | 1 | 7 |
Charlson Comorbidity Index | |||||
0 | 341 (13.6%) | 106 (16.3%) | 105 (13.2%) | 63 (13.0%) | 67 (11.4%) |
1–2 (mild) | 1824 (72.6%) | 471 (72.6%) | 599 (75.4%) | 365 (75.3%) | 389 (66.4%) |
\(\:\ge\:\)3 (moderate/severe) | 349 (13.9%) | 72 (11.1%) | 90 (11.3%) | 57 (11.8%) | 130 (22.2%) |
Missing | 0 | 0 | 0 | 0 | 0 |
Tumor size | |||||
0–20 mm | 1782 (71.0%) | 474 (73.1%) | 578 (73.1%) | 345 (71.1%) | 385 (65.8%) |
21–50 mm | 675 (26.9%) | 162 (25.0%) | 197 (24.9%) | 132 (27.2%) | 184 (31.5%) |
> 50 mm | 52 (2.1%) | 12 (1.9%) | 16 (2.0%) | 8 (1.6%) | 16 (2.7%) |
Missing | 5 | 1 | 3 | 0 | 1 |
Lymph node metastases | |||||
0 | 1560 (62.6%) | 387 (60.2%) | 496 (62.9%) | 304 (63.2%) | 373 (64.3%) |
1–3 | 693 (27.8%) | 196 (30.5%) | 218 (27.6%) | 130 (27.0%) | 149 (25.7%) |
4–9 | 167 (6.7%) | 42 (6.5%) | 52 (6.6%) | 34 (7.1%) | 39 (6.7%) |
\(\:\ge\:\)10 | 73 (2.9%) | 18 (2.8%) | 23 (2.9%) | 13 (2.7%) | 19 (3.3%) |
Missing | 21 | 6 | 5 | 4 | 6 |
Histological classification | |||||
Ductal | 1892 (75.3%) | 474 (73.0%) | 593 (74.7%) | 373 (76.9%) | 452 (77.1%) |
Lobular | 309 (12.3%) | 89 (13.7%) | 101 (12.7%) | 57 (11.8%) | 62 (10.6%) |
Othera | 313 (12.5%) | 86 (13.3%) | 100 (12.6%) | 55 (11.3%) | 72 (12.3%) |
Missing | 0 | 0 | 0 | 0 | 0 |
Histological grade | |||||
Not gradedb | 154 (6.2%) | 43 (6.7%) | 50 (6.5%) | 33 (6.9%) | 28 (4.9%) |
Grade 1 | 579 (23.5%) | 151 (23.6%) | 185 (23.9%) | 108 (22.5%) | 135 (23.4%) |
Grade 2 | 1140 (46.2%) | 282 (44.1%) | 350 (45.2%) | 233 (48.5%) | 275 (47.7%) |
Grade 3 | 596 (24.1%) | 163 (25.5%) | 189 (24.4%) | 106 (22.1%) | 138 (24.0%) |
Missing | 45 | 10 | 20 | 5 | 10 |
ER status (% positive cells) | |||||
0% (negative) | 252 (10.1%) | 89 (13.7%) | 67 (8.5%) | 45 (9.3%) | 51 (8.8%) |
1-100% (positive) | 2249 (89.9%) | 559 (86.3%) | 722 (91.5%) | 438 (90.7%) | 530 (91.2%) |
Missing | 13 | 1 | 5 | 2 | 5 |
HER2 status | |||||
Negative | 2200 (89.3%) | 565 (88.1%) | 701 (90.2%) | 423 (89.8%) | 511 (89.0%) |
Positive | 263 (10.7%) | 76 (11.9%) | 76 (9.8%) | 48 (10.2%) | 63 (11.0%) |
Missing | 51 | 8 | 17 | 14 | 12 |
Final primary surgeryc | |||||
Mastectomy | 829 (33.2%) | 219 (33.9%) | 253 (32.1%) | 151 (31.2%) | 206 (35.4%) |
Lumpectomy | 1671 (66.8%) | 427 (66.1%) | 535 (67.9%) | 333 (68.8%) | 376 (64.6%) |
Missing | 14 | 3 | 6 | 1 | 4 |
Adjuvant radiotherapyd | |||||
No | 488 (20.0%) | 121 (19.1%) | 152 (19.7%) | 90 (19.1%) | 125 (22.2%) |
Yes | 1950 (80.0%) | 512 (80.9%) | 619 (80.3%) | 380 (80.9%) | 439 (77.8%) |
Missing | 76 | 16 | 23 | 15 | 22 |
Endocrine therapyd | |||||
No | 475 (19.5%) | 146 (23.1%) | 133 (17.3%) | 92 (19.6%) | 104 (18.4%) |
Yes | 1963 (80.5%) | 487 (76.9%) | 638 (82.7%) | 378 (80.4%) | 460 (81.6%) |
Missing | 76 | 16 | 23 | 15 | 22 |
Anti-HER2 therapyd | |||||
No | 2179 (89.2%) | 559 (88.0%) | 696 (90.2%) | 421 (89.8%) | 503 (88.9%) |
Yes | 263 (10.8%) | 76 (12.0%) | 76 (9.8%) | 48 (10.2%) | 63 (11.1%) |
Missing | 72 | 14 | 22 | 16 | 20 |
Adjuvant chemotherapyd | |||||
No | 1199 (49.2%) | 235 (37.1%) | 378 (49.0%) | 258 (54.9%) | 328 (58.2%) |
Yes | 1239 (50.8%) | 398 (62.9%) | 393 (51.0%) | 212 (45.1%) | 236 (41.8%) |
Missing | 76 | 16 | 23 | 15 | 22 |